This study is being done to determine if cryptic alterations exist within or near to the ALPL gene in patients with a clinical diagnosis of hypophosphatasia, but without identifiable alteration on commercial testing. Additionally, the study aims to characterize functional effects of certain variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia.
Primary Study Objectives: Determine if cryptic alterations exist within or near to the ALPL gene in patients with clinical diagnosis of hypophosphatasia, but without identifiable pathogenic or likely pathogenic variant on commercial testing. Secondary Study Objective(s): Characterize functional effects of variants of uncertain significance in patients with clinical diagnosis of hypophosphatasia Further characterize the differential diagnosis of hypophosphatasemia in patients with skeletal disease
Study Type
OBSERVATIONAL
Enrollment
66
Whole Genome Sequencing
Children's Mercy Hospital
Kansas City, Missouri, United States
RECRUITINGIdentification of cryptic alterations in the ALPL
Identification of cryptic alterations in the ALPL, with careful focus on cryptic variants within the 12 exons, intronic variants, and variants in regulatory elements. Characterization of loss of function or dominant negative effect in variants which are considered to be of uncertain clinical significance by American College of Medical Genetics guidelines for variants interpretation such that variants are able to be reclassified into actionable (pathogenic, likely pathogenic) or nonactionable (benign, likely benign) class
Time frame: 3 years
Finding of alternate diagnoses among the cohort of nominated patients
Finding of alternate diagnoses among the cohort of nominated patients, expanding the differential diagnosis of hypophosphatasemia
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.